ClinicalTrials.gg
CompletedNCT01602380FALCONUpdated Feb 27, 2026Results posted

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

A Phase 3 interventional study of faslodex 500mg and arimidex 1mg in Hormone Receptor Positive Breast Cancer, sponsored by AstraZeneca. Completed at 118 sites in 20 countries. Open to female participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
462
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
Female
01

Study summary

The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast cancer who have not had prior hormonal treatment.

Read the detailed description

A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg with Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy.

02

Conditions studied

  • Hormone Receptor Positive Breast Cancer

Keywords

  • hormone receptor positive breast cancer
  • endocrine
  • no hormone therapy
  • hormone
  • breast
  • cancer
  • neoplasm
  • metastatic
  • tumour
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 462 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological confirmation of breast cancer in post menopausal women (age >=60). Positive hormone receptor status (ER +ve and/or PgR +ve) of primary or tumour tissue based on local laboratory assessment.
  • EITHER locally advanced disease (1 allowed only if remain unsuitable for therapy of curative intent) OR Metastatic disease. (1 line of chemotherapy for breast cancer allowed only if subsequent evidence of further progressive disease)
  • At least 1 lesion (measurable and/or non-measurable) that can be accurately assessed at baseline and is suitable for repeated assessment.
  • women, fulfilling 1 of:

    • Prior bilateral oophorectomy
    • Age >60 years
    • Age \< 60 years and amenorrheic for 12+months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and FSH and oestradiol in the postmenopausal range

Exclusion criteria

Exclusion Criteria:

  • Presence of life-threatening disease
  • Any of:

    • Extensive hepatic involvement
    • involving brain or meninges
    • symptomatic pulmonary lymph spread
  • Discrete lung metastases are acceptable if respiratory function is not significantly compromised
  • Prior systemic therapy for breast cancer other than one line of cytotoxic chemotherapy (the last dose of chemotherapy must have been received more than 28 days prior to randomisation)
  • Radiation therapy if not completed within 28 days prior to randomisation (with the exception of radiotherapy given for control of bone pain, started prior to randomisation). Prior hormonal treatment for breast cancer.
  • Current or prior within previous 3 years (other than breast cancer or adequately treated basal cell or squamous cell carcinoma of the skin or in situ carcinoma of the cervix).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
462 participants (actual)

Study arms

  • Experimental
    faslodex+placebo

    Blinded: Fulvestrant 500mg intramuscular injection (2x250mg) plus dummy Anastrozole tablets

    Drug: faslodex 500mg · Drug: arimidex dummy

  • Active comparator
    arimidex +placebo

    Blinded: Anastrozole 1mg tablets plus dummy Fulvestrant intramuscular injection (2x0mg)

    Drug: arimidex 1mg · Drug: faslodex dummy

Interventions

  • 2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter

  • oral tablet 1 daily

  • Drugfaslodex dummy

    2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter

  • Drugarimidex dummy

    oral tablet 1 daily

06

What researchers measure

Primary outcomes

  1. Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole

    PFS was defined as the time from randomisation until objective disease progression according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1), surgery or radiotherapy to manage worsening of disease or death by any cause (in the absence of progression). Outcome measure is reported as median time from randomisation to PFS, calculated using the Kaplan-Meier technique.

    Time frame: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)

Secondary outcomes

  1. Comparison of Overall Survival (OS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole; Percentage of Patients With Events

    OS was defined as the time from randomisation until death by any cause. The current OS data correspond to that of the final analysis and the outcome measure is reported as percentage of patients with events.

    Time frame: Baseline (Day 0) up to data cut-off for final analysis (up to approximately 116 months). Following disease progression, patients were to be contacted at 12 weekly intervals to determine survival status

  2. Objective Response Rate (ORR) for Fulvestrant Treatment Versus Anastrozole Treatment

    ORR was defined as the percentage patients with an objective response (i.e. those recording a partial response \[PR\] or complete response \[CR\]) at some point during the study, prior to disease progression. ORR was assessed in patients with measurable disease at baseline only. The determination of measurable disease at baseline was done using baseline RECIST data. CR was disappearance of all target lesions since baseline; was any pathological lymph nodes selected as target lesions (TL) to have a reduction in short axis to \<10 millimeter. PR was at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.

    Time frame: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)

  3. Duration of Response (DoR) for Fulvestrant Treatment Versus Anastrozole Treatment

    DoR was defined only for patients who had an objective response, as the time in days from date of first documentation of response (CR/PR) until date of disease progression. CR was disappearance of all target lesions since baseline; any pathological lymph nodes selected as TL to have a reduction in short axis to \<10 mm. At least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.

    Time frame: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)

  4. Expected Duration of Response (EDoR) for Fulvestrant Treatment Versus Anastrozole Treatment

    EDoR was estimated using the formula EDoR = p Efp(x), where x = DoR, p = proportion of responders, and Efp(x) = mean duration of response for responders. The estimation was completed by using the maximum likelihood estimates of p and Efp(x), as described by Ellis (Ellis S et al. Analysis of duration of response in oncology trials, Contemp Clin Trials 2008; 29:456-65).

    Time frame: Baseline RECIST 1.1 assessments and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)

  5. Clinical Benefit Rate (CBR) for Fulvestrant Treatment Versus Anastrozole Treatment

    CBR was defined as the percentage of patients who had a clinical benefit (i.e. best objective response of CR, PR or stable disease), that was maintained for at least 24 weeks, prior to any evidence of progression. Note that a minimum duration of 22 weeks for CBR was applicable in the analysis (rather than 24 weeks) to allow for the protocolled window of +/-2 weeks.

    Time frame: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)

  6. Duration of Clinical Benefit (DoCB) for Fulvestrant Treatment Versus Anastrozole Treatment

    DoCB was defined only for patients who had clinical benefit, as the time in days from date of randomisation until the date of disease progression.

    Time frame: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)

  7. Expected Duration of Clinical Benefit (EDoCB) for Fulvestrant Treatment Versus Anastrozole Treatment

    EDoCB was estimated using the formula EDoCB = p Efp(x), where x = EDoCB, p = proportion of responders, and Efp(x) = mean duration of response for responders. The estimation was completed by using the maximum likelihood estimates of p and Efp(x), as described by Ellis (Ellis S et al. Analysis of duration of response in oncology trials, Contemp Clin Trials 2008; 29:456-65).

    Time frame: Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)

  8. Comparison of the Effect of Fulvestrant Treatment Versus Anastrozole Treatment on Time to Deterioration of Health-Related Quality of Life (HRQoL)

    The Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire was the instrument selected to assess HRQoL and comprised of following subscales: physical well-being (PWB), functional well-being (FWB), social well-being, emotional well-being, and breast cancer subscale (BCS). The main outcome measure from the FACT-B questionnaire was the Trial Outcome Index (TOI), which was a summary of the following subscales: PWB, FWB, and BCS. Outcome measure is reported as median time to deterioration, defined as the interval from the date of baseline of final analysis to the first assessment of worsened without an improvement in the next 12 weeks in FACT-B TOI, or the date of death (by any cause in the absence of symptom deterioration). Time to deterioration as measured by FACT-B total score was derived similarly and is also reported.

    Time frame: Quality of life questionnaires administered at 3 months post objective disease progression, then at 6-monthly intervals (approximately 75 months)

07

Results

Posted May 17, 2017

Participant flow

First patient enrolled: 17 October 2012.

Participant flow — Overall Study
MilestoneFulvestrant 500 mgAnastrozole 1 mg
Started230232
Completed2531
Not completed205201
Withdrew: Death147145
Withdrew: Withdrawal by subject3941
Withdrew: Lost to follow-up1512
Withdrew: Eligibility criteria not fulfilled23
Withdrew: Other20

Outcome measures

PrimaryComparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole

PFS was defined as the time from randomisation until objective disease progression according to Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1), surgery or radiotherapy to manage worsening of disease or death by any cause (in the absence of progression). Outcome measure is reported as median time from randomisation to PFS, calculated using the Kaplan-Meier technique.

Time frame:
Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)
Reported as:
Median · Months
Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole
MonthsFulvestrant 500 mgAnastrozole 1 mg
Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole16.6 (13.83 to 20.99)13.8 (11.99 to 16.59)
Statistical analysis
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Log Rank · p = 0.0486 (2-sided p-value) · Hazard ratio (hr): 0.797 · 95% CI 0.637 to 0.999A hazard ratio \< 1 favours fulvestrant.
SecondaryComparison of Overall Survival (OS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole; Percentage of Patients With Events

OS was defined as the time from randomisation until death by any cause. The current OS data correspond to that of the final analysis and the outcome measure is reported as percentage of patients with events.

Time frame:
Baseline (Day 0) up to data cut-off for final analysis (up to approximately 116 months). Following disease progression, patients were to be contacted at 12 weekly intervals to determine survival status
Reported as:
Number · Percentage of patients
Comparison of Overall Survival (OS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole; Percentage of Patients With Events
Percentage of patientsFulvestrant 500 mgAnastrozole 1 mg
Comparison of Overall Survival (OS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole; Percentage of Patients With Events68.367.7
Statistical analysis
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Log Rank · p = 0.7579 (2-sided p-value) · Hazard ratio (hr): 0.966 · 95% CI 0.773 to 1.206A HR of \<1 favours fulvestrant.
SecondaryObjective Response Rate (ORR) for Fulvestrant Treatment Versus Anastrozole Treatment

ORR was defined as the percentage patients with an objective response (i.e. those recording a partial response \[PR\] or complete response \[CR\]) at some point during the study, prior to disease progression. ORR was assessed in patients with measurable disease at baseline only. The determination of measurable disease at baseline was done using baseline RECIST data. CR was disappearance of all target lesions since baseline; was any pathological lymph nodes selected as target lesions (TL) to have a reduction in short axis to \<10 millimeter. PR was at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.

Time frame:
Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) for Fulvestrant Treatment Versus Anastrozole Treatment
Percentage of participantsFulvestrant 500 mgAnastrozole 1 mg
Objective Response Rate (ORR) for Fulvestrant Treatment Versus Anastrozole Treatment46.144.9
Statistical analysis
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Regression, Logistic · p = 0.7290 (2-sided p-value) · Odds ratio (or): 1.074 · 95% CI 0.716 to 1.614
SecondaryDuration of Response (DoR) for Fulvestrant Treatment Versus Anastrozole Treatment

DoR was defined only for patients who had an objective response, as the time in days from date of first documentation of response (CR/PR) until date of disease progression. CR was disappearance of all target lesions since baseline; any pathological lymph nodes selected as TL to have a reduction in short axis to \<10 mm. At least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.

Time frame:
Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)
Reported as:
Median · Months
Duration of Response (DoR) for Fulvestrant Treatment Versus Anastrozole Treatment
MonthsFulvestrant 500 mgAnastrozole 1 mg
Duration of Response (DoR) for Fulvestrant Treatment Versus Anastrozole Treatment20.0 (10.6 to NA)13.2 (8.3 to 24.7)
SecondaryExpected Duration of Response (EDoR) for Fulvestrant Treatment Versus Anastrozole Treatment

EDoR was estimated using the formula EDoR = p Efp(x), where x = DoR, p = proportion of responders, and Efp(x) = mean duration of response for responders. The estimation was completed by using the maximum likelihood estimates of p and Efp(x), as described by Ellis (Ellis S et al. Analysis of duration of response in oncology trials, Contemp Clin Trials 2008; 29:456-65).

Time frame:
Baseline RECIST 1.1 assessments and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)
Reported as:
Number · Days
Expected Duration of Response (EDoR) for Fulvestrant Treatment Versus Anastrozole Treatment
DaysFulvestrant 500 mgAnastrozole 1 mg
Expected Duration of Response (EDoR) for Fulvestrant Treatment Versus Anastrozole Treatment346.84227.58
Statistical analysis
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Method of Ellis et al · p = 0.0367 (2-sided p-value) · Rato of edor: 1.52 · 95% CI 1.03 to 2.26
SecondaryClinical Benefit Rate (CBR) for Fulvestrant Treatment Versus Anastrozole Treatment

CBR was defined as the percentage of patients who had a clinical benefit (i.e. best objective response of CR, PR or stable disease), that was maintained for at least 24 weeks, prior to any evidence of progression. Note that a minimum duration of 22 weeks for CBR was applicable in the analysis (rather than 24 weeks) to allow for the protocolled window of +/-2 weeks.

Time frame:
Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR) for Fulvestrant Treatment Versus Anastrozole Treatment
Percentage of participantsFulvestrant 500 mgAnastrozole 1 mg
Clinical Benefit Rate (CBR) for Fulvestrant Treatment Versus Anastrozole Treatment78.374.1
Statistical analysis
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Regression, Logistic · p = 0.3045 (2-sided p-value) · Odds ratio (or): 1.253 · 95% CI 0.815 to 1.932
SecondaryDuration of Clinical Benefit (DoCB) for Fulvestrant Treatment Versus Anastrozole Treatment

DoCB was defined only for patients who had clinical benefit, as the time in days from date of randomisation until the date of disease progression.

Time frame:
Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)
Reported as:
Median · Months
Duration of Clinical Benefit (DoCB) for Fulvestrant Treatment Versus Anastrozole Treatment
MonthsFulvestrant 500 mgAnastrozole 1 mg
Duration of Clinical Benefit (DoCB) for Fulvestrant Treatment Versus Anastrozole Treatment22.1 (11.2 to NA)19.1 (11.3 to 30.4)
SecondaryExpected Duration of Clinical Benefit (EDoCB) for Fulvestrant Treatment Versus Anastrozole Treatment

EDoCB was estimated using the formula EDoCB = p Efp(x), where x = EDoCB, p = proportion of responders, and Efp(x) = mean duration of response for responders. The estimation was completed by using the maximum likelihood estimates of p and Efp(x), as described by Ellis (Ellis S et al. Analysis of duration of response in oncology trials, Contemp Clin Trials 2008; 29:456-65).

Time frame:
Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until disease progression or treatment discontinuation (up to approximately 38 months)
Reported as:
Number · Days
Expected Duration of Clinical Benefit (EDoCB) for Fulvestrant Treatment Versus Anastrozole Treatment
DaysFulvestrant 500 mgAnastrozole 1 mg
Expected Duration of Clinical Benefit (EDoCB) for Fulvestrant Treatment Versus Anastrozole Treatment667.94532.04
Statistical analysis
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Method of Ellis et al · p = 0.0561 (2-sided p-value) · Ratio of edocb: 1.26 · 95% CI 0.99 to 1.59
SecondaryComparison of the Effect of Fulvestrant Treatment Versus Anastrozole Treatment on Time to Deterioration of Health-Related Quality of Life (HRQoL)

The Functional Assessment of Cancer Therapy - Breast (FACT-B) questionnaire was the instrument selected to assess HRQoL and comprised of following subscales: physical well-being (PWB), functional well-being (FWB), social well-being, emotional well-being, and breast cancer subscale (BCS). The main outcome measure from the FACT-B questionnaire was the Trial Outcome Index (TOI), which was a summary of the following subscales: PWB, FWB, and BCS. Outcome measure is reported as median time to deterioration, defined as the interval from the date of baseline of final analysis to the first assessment of worsened without an improvement in the next 12 weeks in FACT-B TOI, or the date of death (by any cause in the absence of symptom deterioration). Time to deterioration as measured by FACT-B total score was derived similarly and is also reported.

Time frame:
Quality of life questionnaires administered at 3 months post objective disease progression, then at 6-monthly intervals (approximately 75 months)
Reported as:
Median · months
Comparison of the Effect of Fulvestrant Treatment Versus Anastrozole Treatment on Time to Deterioration of Health-Related Quality of Life (HRQoL)
monthsFulvestrant 500 mgAnastrozole 1 mg
Time to TOI deterioration14.1 (5.5 to 44.1)11.1 (5.5 to 38.3)
Time to FACT-B total score deterioration13.8 (5.5 to 38.7)11.1 (4.8 to 33.6)
Statistical analysis
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Log Rank · p = 0.2846 (2-sided p-value) · Hazard ratio (hr): 0.88 · 95% CI 0.70 to 1.11A hazard ratio \< 1 favours fulvestrant.
  • Fulvestrant 500 mg vs Anastrozole 1 mg · Log Rank · p = 0.0844 (2-sided p-value) · Hazard ratio (hr): 0.82 · 95% CI 0.66 to 1.03A hazard ratio \< 1 favours fulvestrant.

Adverse events

Collected over 116 months (duration from first patient enrolled to data cut-off for the final analysis). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fulvestrant 500 mg157/230 (68.3%)39/228 (17.1%)125/228 (54.8%)
Anastrozole 1 mg159/232 (68.5%)36/232 (15.5%)127/232 (54.7%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventFulvestrant 500 mgAnastrozole 1 mg
Pleural effusionRespiratory, thoracic and mediastinal disorders7/2282/232
PneumoniaInfections and infestations3/2284/232
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/2281/232
Cardiac failureCardiac disorders0/2283/232
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2283/232
PeritonitisInfections and infestations2/2280/232
Urinary tract infectionInfections and infestations2/2280/232
Radius fractureInjury, poisoning and procedural complications2/2280/232
Cerebrovascular accidentNervous system disorders2/2280/232
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/2280/232
Most frequent other events
Showing 10 of 20
Most frequent other events
EventFulvestrant 500 mgAnastrozole 1 mg
ArthralgiaMusculoskeletal and connective tissue disorders42/22831/232
FatigueGeneral disorders29/22818/232
Hot flushVascular disorders26/22824/232
NauseaGastrointestinal disorders25/22825/232
Back painMusculoskeletal and connective tissue disorders22/22818/232
HypertensionVascular disorders18/22822/232
AnaemiaBlood and lymphatic system disorders9/22820/232
InsomniaPsychiatric disorders18/22815/232
Pain in extremityMusculoskeletal and connective tissue disorders17/22811/232
Alanine aminotransferase increasedInvestigations16/2288/232

Baseline characteristics

The intention to treat (ITT) analysis set included all randomised patients.

Age, Continuous
Age, Continuous(years)Fulvestrant 500 mgAnastrozole 1 mgTotal
Mean63.8 ± 9.8663.3 ± 10.3863.5 ± 10.12
Sex: Female, Male
Sex: Female, Male(Participants)Fulvestrant 500 mgAnastrozole 1 mgTotal
Female230232462
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fulvestrant 500 mgAnastrozole 1 mgTotal
American Indian or Alaska Native156
Asian363470
Black or African American448
White175174349
Other141529
08

Study locations

118 sites
  • Research Site
    Modesto, California 95355, United States
  • Research Site
    Savannah, Georgia 31405, United States
  • Research Site
    Auburn, Maine 04212, United States
  • Research Site
    Worcester, Massachusetts 01608, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Lincoln, Nebraska 68506, United States
  • Research Site
    Somerset, New Jersey 08873, United States
  • Research Site
    Columbus, Ohio 43202, United States
  • Research Site
    Montgomery, Ohio 45242, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Salt Lake City, Utah 84107, United States
  • Research Site
    La Rioja, 5300, Argentina
  • Research Site
    Mar del Plata, B7600CTO, Argentina
  • Research Site
    Pergamino, B2700CPM, Argentina
  • Research Site
    Rosario, S2000KZE, Argentina
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Santo André, 09060-870, Brazil
  • Research Site
    Abbotsford British Columbia, British Columbia V2S0C2, Canada
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Kitchener, Ontario N2G 1G3, Canada
  • Research Site
    Thunder Bay, Ontario P7B 6V4, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Dalian, 116011, China
  • Research Site
    Fuzhou, 350025, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Suzhou, 215004, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Prague, 150 06, Czechia
  • Research Site
    Příbram, 261 01, Czechia
  • Research Site
    Avellino, 83100, Italy
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Benevento, 82100, Italy
  • Research Site
    Catania, 95126, Italy
  • Research Site
    Genova, 16128, Italy
  • Research Site
    Pisa, 56100, Italy
  • Research Site
    Roma, 00100, Italy
  • Research Site
    Roma, 00144, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Treviglio, 24047, Italy
  • Research Site
    Fukuoka, 811-1395, Japan
  • Research Site
    Hamamatsu, 430-0906, Japan
  • Research Site
    Kagoshima, 892-0833, Japan
  • Research Site
    Kumamoto, 860-8556, Japan
  • Research Site
    Matsuyama, 791-0280, Japan
  • Research Site
    Mitaka-shi, 181-8611, Japan
  • Research Site
    Nishinomiya-shi, 663-8501, Japan
  • Research Site
    Osaka, 540-0006, Japan
  • Research Site
    Sakaishi, 590-0064, Japan
  • Research Site
    Suita-shi, 565-0871, Japan
  • Research Site
    Mexico City, 6760, Mexico
  • Research Site
    Mérida, 97000, Mexico
  • Research Site
    Monterrey, 64000, Mexico
  • Research Site
    Monterrey, 64060, Mexico
  • Research Site
    Monterrey, 64710, Mexico
  • Research Site
    Lima, Lima 18, Peru
  • Research Site
    Lima, LIMA 27, Peru
  • Research Site
    Lima, LIMA 33, Peru
  • Research Site
    Lima, LIMA 41, Peru
  • Research Site
    Katowice, 40-635, Poland
  • Research Site
    Lodz, 90-242, Poland
  • Research Site
    Lublin, 20-718, Poland
  • Research Site
    Brăila, 810325, Romania
  • Research Site
    Craiova, 200347, Romania
  • Research Site
    Onești, 601048, Romania
  • Research Site
    Timișoara, 300239, Romania
  • Research Site
    Barnaul, 656052, Russia
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Omsk, 644013, Russia
  • Research Site
    Ryazan, 390046, Russia
  • Research Site
    Saint Petersburg, 191014, Russia
  • Research Site
    Saint Petersburg, 195271, Russia
  • Research Site
    Saint Petersburg, 197022, Russia
  • Research Site
    Saint Petersburg, 197758, Russia
  • Research Site
    Tomsk, 634028, Russia
  • Research Site
    Bardejov, 085 01, Slovakia
  • Research Site
    Bratislava, 814 65, Slovakia
  • Research Site
    Bratislava, 833 10, Slovakia
  • Research Site
    Trenčín, 91171, Slovakia
  • Research Site
    Cape Town, 7570, South Africa
  • Research Site
    Cape Town, 7700, South Africa
  • Research Site
    Cape Town, 7925, South Africa
  • Research Site
    Pietermaritzburg, 3201, South Africa
  • Research Site
    Pretoria, 0001, South Africa
  • Research Site
    Pretoria, 0081, South Africa
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28050, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Pozuelo de Alarcón, 28223, Spain
  • Research Site
    Sabadell, 8208, Spain
  • Research Site
    Seville, 41009, Spain
  • Research Site
    Seville, 41013, Spain
  • Research Site
    Seville, 41014, Spain
  • Research Site
    Valencia, 46014, Spain
  • Research Site
    Valencia, 46026, Spain
  • Research Site
    Taichung, 40447, Taiwan

Showing the first 100 of 118 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Robertson JFR, Shao Z, Noguchi S, Bondarenko I, Panasci L, Singh S, Subramaniam S, Ellis MJ. Fulvestrant Versus Anastrozole in Endocrine Therapy-Naive Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial. J Clin Oncol. 2025 May;43(13):1539-1545. doi: 10.1200/JCO.24.00994. Epub 2025 Jan 7. PubMed 39772884 ↗
  • Robertson JFR, Cheung KL, Noguchi S, Shao Z, Degboe A, Lichfield J, Thirlwell J, Fazal M, Ellis MJ. Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. Eur J Cancer. 2018 May;94:206-215. doi: 10.1016/j.ejca.2018.02.026. Epub 2018 Mar 22. PubMed 29574365 ↗
  • Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016 Dec 17;388(10063):2997-3005. doi: 10.1016/S0140-6736(16)32389-3. Epub 2016 Nov 29. PubMed 27908454 ↗
  • Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiowka M, Hewson N, Rukazenkov Y, Robertson JF. Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. J Clin Oncol. 2015 Nov 10;33(32):3781-7. doi: 10.1200/JCO.2015.61.5831. Epub 2015 Sep 14. PubMed 26371134 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Apr 2016, 41 months.

Results were first posted in May 2017, 1 year 1 month after primary completion.

Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 41 months is close to that.

Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2012
First posted
May 21, 2012
StartActual
Oct 17, 2012
Primary completionActual
Apr 11, 2016
CompletionActual
Jan 16, 2026
Results first posted
May 17, 2017
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01602380
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 21, 2012
Start date
Oct 17, 2012
Primary completion
Apr 11, 2016
Completion
Jan 16, 2026
Results posted
May 17, 2017
Last update
Feb 27, 2026

Study contacts

Shankar S, MD
study director · AstraZeneca
John Robertson, MD
principal investigator · Graduate Medicine and Health School, University of Nottingham, UK
Matthew Ellis, DM
principal investigator · Washington University School of Medicine, USA
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion